Biopharma | June 02, 2026
Aragen completes commercial-scale GMP manufacturing of Daretabart in 9 months
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
